All In Biotech

Free tool

FAERS Monitor: Jatenzo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206089 or its brand name (Jatenzo, Testosterone Undecanoate). Reports on generic versions are filed under their own applications.

Reports

563

Serious

270

48% of reports

Hospitalization

106

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use60
  • drug ineffective33
  • fatigue28
  • blood testosterone decreased25
  • headache25
  • therapy interrupted25
  • blood testosterone abnormal22
  • intentional product use issue22
  • product availability issue19
  • polycythaemia16
  • blood pressure increased15
  • asthenia14
  • blood testosterone increased14
  • haematocrit increased14
  • product dose omission issue14

Reports by year received

View as table
YearReports
20042
20051
20061
20093
20106
20112
20129
20135
20144
201512
20167
20175
201822
20198
202019
202146
202229
2023107
2024106
2025100
202669

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,596 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood testosterone abnormalSignal22758.2501.215,574
polycythaemiaSignal16292.0179.84,320
blood testosterone increasedSignal14244.9145.73,141
haematocrit increasedSignal14230.9137.42,961
blood testosterone decreasedSignal25137.093.33,231
product availability issueSignal1931.220.0526
therapy interruptedSignal2513.18.9268
intentional product use issueSignal229.46.2157
blood pressure increasedSignal153.72.227
off label useSignal602.62.058
product dose omission issue141.81.14
headache251.51.04
asthenia141.40.81
fatigue281.30.92
drug ineffective330.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.